A genomewide scan for loci predisposing to type 2 diabetes in a UK population (the Diabetes UK Warren 2 repository): Analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q

被引:243
|
作者
Wiltshire, S
Hattersley, AT
Hitman, GA
Walker, M
Levy, JC
Sampson, M
O'Rahilly, S
Frayling, TM
Bell, JI
Lathrop, GM
Bennett, A
Dhillon, R
Fletcher, C
Groves, CJ
Jones, E
Prestwich, P
Simecek, N
Rao, PVS
Wishart, M
Foxon, R
Howell, S
Smedley, D
Cardon, LR
Menzel, S
McCarthy, MI
机构
[1] Kings Coll London, Imperial Coll Genet & Genom Res Inst, London W12 0NN, England
[2] Kings Coll London, Imperial Coll, Div Med, London W12 0NN, England
[3] Kings Coll London, St Bartholomews & Royal London Sch Med & Dent, Dept Med, London W12 0NN, England
[4] Kings Coll London, Sch Biomed Sci, London W12 0NN, England
[5] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England
[6] Univ Oxford, Radcliffe Infirm, Oxford OX2 6HE, England
[7] Univ Oxford, Buffield Dept Med, Oxford OX2 6HE, England
[8] Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Diabet & Vasc Med, Exeter, Devon, England
[9] Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[10] Norfolk & Norwich Univ Hosp, Dept Endocrinol & Diabet, Norwich, Norfolk, England
[11] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
[12] Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England
基金
英国惠康基金;
关键词
D O I
10.1086/323249
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Improved molecular understanding of the pathogenesis of type 2 diabetes is essential if current therapeutic and preventative options are to be extended. To identify diabetes-susceptibility genes, we have completed a primary (418-marker, 9-cM) autosomal-genome scan of 743 sib pairs (573 pedigrees) with type 2 diabetes who are from the Diabetes UK Warren 2 repository. Nonparametric linkage analysis of the entire data set identified seven regions showing evidence for linkage, with allele-sharing LOD scores greater than or equal to1.18 (P less than or equal to .01). The strongest evidence was seen on chromosomes 8p21-22 (near D8S258 [LOD score 2.55]) and 10q23.3 (near D10S1765 [LOD score 1.99]), both coinciding with regions identified in previous scans in European subjects. This was also true of two lesser regions identified, on chromosomes 5q13 (D5S647 [LOD score 1.22] and 5q32 (D5S436 [LOD score 1.22]). Loci on 7p15.3 (LOD score 1.31) and 8q24.2 (LOD score 1.41) are novel. The final region showing evidence for linkage, on chromosome 1q24-25 (near D1S218 [LOD score 1.50]), colocalizes with evidence for linkage to diabetes found in Utah, French, and Pima families and in the GK rat. After dense-map genotyping (mean marker spacing 4.4 cM), evidence for linkage to this region increased to a LOD score of 1.98. Conditional analyses revealed nominally significant interactions between this locus and the regions on chromosomes 10q23.3 (P = .01) and 5q32 ( P = .02). These data, derived from one of the largest genome scans undertaken in this condition, confirm that individual susceptibility-gene effects for type 2 diabetes are likely to be modest in size. Taken with genome scans in other populations, they provide both replication of previous evidence indicating the presence of a diabetes-susceptibility locus on chromosome 1q24-25 and support for the existence of additional loci on chromosomes 5, 8, and 10. These data should accelerate positional cloning efforts in these regions of interest.
引用
收藏
页码:553 / 569
页数:17
相关论文
共 41 条
  • [41] Risk of Kidney Stones Following SGLT2i-and GLP1-RA Initiation Among Patients with Type 2 Diabetes in Denmark, Norway, UK, and Taiwan: Population-Based Active Comparator, New User Cohort Studies and Meta-Analysis
    Lund, Lars Christian
    Abtahi, Shahab
    Gulseth, Hanne L. Lovdal
    Hsieh, Miyuki Hsing-Chun
    Ruiz, Paz Lopez-Doriga
    Souverein, Patrick C.
    de la Torre, Adrian Martinez
    Burden, Andrea Michelle
    Karlstad, Oystein
    Klungel, Olaf H.
    Lai, Edward Chia-Cheng
    Pottegard, Anton
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 105 - 106